Today: 28 January 2026
Subscribe
Browse Category

Pharmaceutical Industry News 23 November 2025 - 4 December 2025

Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon Ltd. (NASDAQ: PLRZ) has exploded into the spotlight after a two‑day run that has turned an obscure micro‑cap biotech into one of the most talked‑about healthcare stocks on the Nasdaq. By early afternoon on December 4, 2025, Polyrizon shares were trading around $13–15, nearly doubling from Wednesday’s close at $7.09, with intraday highs reported above $18 and gains briefly…
4 December 2025
····
Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics’ stock exploded higher on December 3, 2025 after the biotech announced that its pivotal Phase 3 HOPE‑3 trial of Deramiocel (CAP‑1002) in Duchenne muscular dystrophy (DMD) met both its primary and key secondary endpoints. GlobeNewswire Below is a deep dive into today’s news, the regulatory backdrop, the company’s finances and pipeline, and how analysts have been thinking about…
3 December 2025
····
Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (NYSE: BMY) has suddenly become one of the most eventful big pharma names to watch as of December 1, 2025. A major lawsuit has been allowed to proceed, new cell therapy approvals are landing, hematology data at ASH 2025 is impressive, and investors are reassessing the stock’s value, dividend and medium‑term growth story. Below is a deep dive…
2 December 2025
····
Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer Inc. (NYSE: PFE) is back in the spotlight as of November 30, 2025. Fresh regulatory filings show new institutional buying, analysts are nudging price targets higher, and the company has closed a multibillion‑dollar obesity deal while reshaping its post‑pandemic pipeline. This article pulls together the most relevant current Pfizer stock news as of November 30, 2025, and explains what…
30 November 2025
····
Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Published: November 29, 2025 Merck & Co., Inc. (NYSE: MRK) heads into the last month of 2025 riding a powerful wave of oncology wins, big‑ticket acquisitions and fresh analyst upgrades that have pushed the stock to new 52‑week highs. As of the close on Friday, November 28, Merck shares finished at $104.83, just off a record intraday high of $105.84…
29 November 2025
····
Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly and Company (NYSE: LLY) is catching its breath after one of the wildest runs any pharmaceutical stock has ever seen. On November 29, 2025, the share price is easing off record highs, but the company is still hovering near the rarefied air of a trillion‑dollar valuation and sitting on massive gains for the year. Smartkarma This piece walks…
29 November 2025
····
Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

On Friday, 28 November 2025, Merck & Co., Inc. (NYSE: MRK) continued to trade near its 52‑week highs as a wave of fresh institutional filings, bullish research notes, and recent oncology approvals kept the spotlight firmly on the pharmaceutical giant. The stock closed around $104.5 per share, after trading between roughly $104 and $105 on the day, leaving Merck’s market…
28 November 2025
····
AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie Inc. (NYSE: ABBV) is trading lower today, but the big pharma giant remains near multi-year highs as investors digest a powerful mix of good news (a major FDA approval, strong Q3 numbers) and growing policy headwinds from U.S. Medicare drug price cuts. Below is a full wrap-up of what’s happening with AbbVie stock today, November 26, 2025, and the…
26 November 2025
···
PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

Pfizer Inc. (NYSE: PFE) is back on many traders’ screens today. As of early afternoon on Tuesday, November 25, 2025, Pfizer shares are trading around $25.65, up roughly 1.7% on the session, after touching an intraday high near $25.96 and a low around $25.24. That puts PFE stock in the middle of its 52‑week range between $20.92 and $27.69, with…
25 November 2025
···
ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

Key Takeaways ALT stock price today: how Altimmune is trading on November 25, 2025 Altimmune Inc. (NASDAQ: ALT) continues its November rebound. As of early trading on Tuesday, November 25, ALT is changing hands around $5.1 per share, roughly flat to slightly higher versus Monday’s close. Intraday ranges have been tight so far, with trading largely clustered between about $4.8…
25 November 2025
····
Johnson & Johnson (JNJ) Stock on November 25, 2025: Ex‑Dividend Day, Options Surge and a $3 Billion Cancer Bet

Johnson & Johnson (JNJ) Stock on November 25, 2025: Ex‑Dividend Day, Options Surge and a $3 Billion Cancer Bet

Date: November 25, 2025 Johnson & Johnson (NYSE: JNJ) heads into Tuesday’s session at or near record highs, riding a wave of bullish options activity, a key ex‑dividend date today and a string of growth-focused pipeline moves in cancer and neuroscience. As of the latest completed trading session on Monday, November 24, JNJ was trading around $206 per share, close…
25 November 2025
····
Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly’s stock is entering the new week as one of the most closely watched names on Wall Street. As of this weekend (Sunday, November 23, 2025), LLY is trading near $1,060 per share, valuing the company at roughly $1 trillion, after becoming the first drugmaker ever to join the trillion‑dollar market‑cap club. Reuters At the same time, new headlines…
23 November 2025
····
1 … 7 8 9 10 11

Stock Market Today

  • Copper Rises as Alternative to Gold, Silver After Rally
    January 28, 2026, 2:05 AM EST. Investors who missed the sharp rally in gold (up 95%) and silver (up 200%) are eyeing copper as a promising alternative metal investment. Copper surged 50% domestically in 2025, fueled by U.S. tariffs on copper products, mine outages, and supply constraints from labor unrest in Chile and Peru. Tariffs and tight inventories in China, Russia, and Europe have created scarcity and potential price volatility. Analysts predict copper's bull market will continue into 2026 amid ongoing supply challenges and rising demand. Copper's role as a critical industrial metal makes it an appealing candidate for investors wary of gold and silver's elevated valuations.
Go toTop